Literature DB >> 30948018

Generation, expression and utilization of single-domain antibodies for in vivo protein localization and manipulation in sea urchin embryos.

Catherine S Schrankel1, Tufan Gökirmak1, Chang-Wook Lee2, Geoffrey Chang2, Amro Hamdoun3.   

Abstract

Single-domain antibodies, also known as nanobodies, are small antigen-binding fragments (~15kDa) that are derived from heavy chain only antibodies present in camelids (VHH, from camels and llamas), and cartilaginous fishes (VNAR, from sharks). Nanobody V-like domains are useful alternatives to conventional antibodies due to their small size, and high solubility and stability across many applications. In addition, phage display, ribosome display, and mRNA/cDNA display methods can be used for the efficient generation and optimization of binders in vitro. The resulting nanobodies can be genetically encoded, tagged, and expressed in cells for in vivo localization and functional studies of target proteins. Collectively, these properties make nanobodies ideal for use within echinoderm embryos. This chapter describes the optimization and imaging of genetically encoded nanobodies in the sea urchin embryo. Examples of live-cell antigen tagging (LCAT) and the manipulation of green fluorescent protein (GFP) are shown. We discuss the potentially transformative applications of nanobody technology for probing membrane protein trafficking, cytoskeleton re-organization, receptor signaling events, and gene regulation during echinoderm development.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chromobody; Development; Live-cell antigen tagging; Nanobody; mRNA overexpression

Mesh:

Substances:

Year:  2019        PMID: 30948018      PMCID: PMC6489465          DOI: 10.1016/bs.mcb.2018.11.005

Source DB:  PubMed          Journal:  Methods Cell Biol        ISSN: 0091-679X            Impact factor:   1.441


  2 in total

1.  Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.

Authors:  Edwin J Velazquez; Jordan D Cress; Tyler B Humpherys; Toni O Mortimer; David M Bellini; Jonathan R Skidmore; Kathryn R Smith; Richard A Robison; Scott K Weber; Kim L O'Neill
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

2.  Good reasons for targeting SARS-CoV-2 by engineered extracellular vesicles.

Authors:  Ario de Marco; Lucio Barile
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-09       Impact factor: 6.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.